https://www.selleckchem.com/JAK.html
s and balloon lengths. Compared to conventional HPB angioplasty, DCB treatment achieved superior primary patency defined using PSVR measured at 6 months and superior intervention-free survival of both the target lesion and the target shunt at 12 months without evidence of greater adverse events. Funded by ZhuHai Cardionovum Medical Device Co., Ltd. Registered at ClinicalTrials.gov with study number NCT02962141. Registered at ClinicalTrials.gov with study number NCT02962141. To identify differences in socioeconomic factors (SES) and subclinical cardi
Curtir
Comentario
Compartilhar
